PART1 Participants in Part 1 (Run-in-Phase) of study will receive Tocilizumab (TCZ)
(RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2
weeks (Q2W) for up to 24 weeks. Participants who experience a laboratory abnormality during
part 1 may be eligible to move into Part 2 of the study.
PART 2 This open-label Phase IV study will evaluate the efficacy, safety, pharmacokinetics,
pharmacodynamics and immunogenicity of RoActemra/Actemra (tocilizumab) in reduced dose
frequency in participants with adequately controlled systemic juvenile idiopathic arthritis
who have experienced a laboratory abnormality on twice weekly RoActemra/Actemra dosing, that
has since resolved. Participants will receive RoActemra/Actemra 12 mg/kg or 8 mg/kg
intravenously every 3 weeks. After 5 consecutive infusions, participants who experience an
event of neutropenia, thrombocytopenia or liver enzyme abnormality will move to every 4 weeks
RoActemra/Actemra administration. Anticipated time on study treatment is 52 weeks.